Search results
Metis Global Partners LLC Sells 549 Shares of Incyte Co. (NASDAQ:INCY)
ETF DAILY NEWS· 6 days agoMetis Global Partners LLC lessened its holdings in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 6.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned ...
Allogene Therapeutics (NASDAQ:ALLO) Trading Up 9.5% on Analyst Upgrade
ETF DAILY NEWS· 18 hours agoAllogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report)’s share price traded up 9.5% during trading on Wednesday after Stifel Nicolaus raised their price target on the stock from $4.40 to ...
Q3 2024 EPS Estimates for Beam Therapeutics Inc. Boosted by Analyst (NASDAQ:BEAM)
ETF DAILY NEWS· 6 days agoBeam Therapeutics Inc. (NASDAQ:BEAM – Free Report) – Research analysts at Leerink Partnrs upped their Q3 2024 EPS estimates for Beam Therapeutics in a research report issued on Tuesday, May ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Up 8.0% in April
ETF DAILY NEWS· 18 hours agoAllogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totalling 33,870,000 ...
Amgen Inc. (AMGN) To Go Ex-Dividend on May 16th
ETF DAILY NEWS· 3 days agoAmgen Inc. (NASDAQ:AMGN – Get Free Report) announced a quarterly dividend on Wednesday, March 6th, RTT News reports. This represents a $9.00 annualized dividend and a dividend yield of 2.92% ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days agoVincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of “Hold” from Brokerages
ETF DAILY NEWS· 3 days agoShares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have been given a consensus rating of “Hold” by the thirteen ratings firms that are covering the stock, MarketBeat Ratings reports ...